Literature DB >> 12940655

Use of biperiden hydrochloride in a child with severe dyskinesia induced by phenytoin.

Hüseyin Caksen1, Dursun Odabaş, Omer Anlar.   

Abstract

A 5-year-old girl was admitted with a 3-day history of speech disorder and gait abnormality. She had been diagnosed with idiopathic epilepsy and was given phenytoin 2 months before admission to our hospital. On physical examination, she had severe lingual-facial-buccal extrapyramidal movements, slurred speech, and ataxic gait. During examination, she was repetitively scratching her scalp with her right hand every 30 to 60 seconds. Serum phenytoin level was 10 microg/mL (normal 8-20 microg/mL). Electroencephalography showed diffuse slow waves. Magnetic resonance imaging of the brain was normal. During hospitalization, her abnormal findings were thought to be attributable to phenytoin; it was immediately discontinued, and biperiden was initiated. After biperiden was administered, her abnormal movements markedly decreased; later, they almost completely disappeared. In conclusion, we would like to emphasize that severe dyskinesia can be observed during phenytoin therapy and that biperiden can be successfully used in the treatment of this unpleasant condition.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12940655     DOI: 10.1177/08830738030180070101

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  2 in total

1.  Characterization of phenytoin, carbamazepine, vinpocetine and clorgyline simultaneous effects on sodium channels and catecholamine metabolism in rat striatal nerve endings.

Authors:  María Sitges; Blanca I Aldana; Luz M Chiu; Vladimir Nekrassov
Journal:  Neurochem Res       Date:  2008-08-19       Impact factor: 3.996

2.  Aripiprazole-induced Tardive Dyskinesia in 13 Years Old Girl Successfully Treated with Biperiden: A Case Report.

Authors:  Marco Lamberti; Gabriella Di Rosa; Francesca Cucinotta; Erica Pironti; Cecilia Galati; Antonella Gagliano
Journal:  Clin Psychopharmacol Neurosci       Date:  2017-08-31       Impact factor: 2.582

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.